Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | ARF6 | P62330 | 1/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30807084 | 0.91 | SLC6A4 (0.39) | SCN9APLA2G7PTGER1 | |
| SCHEMBL21786611 | 0.91 | SLC6A4 (0.39) | SCN9APLA2G7PTGER1 | |
| SCHEMBL29653521 | 0.91 | SLC6A4 (0.39) | SCN9APLA2G7PTGER1 | |
| SCHEMBL21786621 | 0.90 | ARF6 (0.40) | SCN9AARF6KDM4EALDH1A1POLB | |
| SCHEMBL22787009 | 0.89 | PTGER1 (0.36) | CTSSPLA2G7PTGER1MRGPRX4 | |
| SCHEMBL31635988 | 0.89 | PTGER1 (0.36) | CTSSPLA2G7PTGER1MRGPRX4 | |
| SCHEMBL22790970 | 0.86 | CTSS (0.38) | NSD2CTSSARF6PLA2G7KDM4E | |
| SCHEMBL27349291 | 0.85 | PTGDR2 (0.34) | PLA2G7PTGER1 | |
| SCHEMBL23913085 | 0.85 | MRGPRX4 (0.40) | SCN9AARF6PTGER1PRKDCMRGPRX4 | |
| SCHEMBL21786465 | 0.84 | SLC6A4 (0.39) | SCN9AMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | NORTHWESTERN UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| WO-2020257261-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2020046382-A1 | SUBSTITUTED HETEROCYCLES AS C-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | SCN9A 4686/4885NSD2 464/4885CTSS 3105/4885 |
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | MYC, MYCBP, MYCBP2 | SCN9A 4686/4885NSD2 464/4885CTSS 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.